Prime Medicine, Inc. (PRME)
NASDAQ: PRME · Real-Time Price · USD
3.570
-0.020 (-0.56%)
At close: Sep 1, 2026, 4:00 PM EDT
3.540
-0.030 (-0.84%)
After-hours: Sep 1, 2026, 7:47 PM EDT
Prime Medicine Revenue
Prime Medicine had revenue of $1.15M in the quarter ending June 30, 2026, with 3.50% growth. This brings the company's revenue in the last twelve months to $4.07M, down -17.90% year-over-year. In the year 2025, Prime Medicine had annual revenue of $4.63M with 55.28% growth.
Revenue (ttm)
$4.07M
Revenue Growth
-17.90%
P/S Ratio
155.93
Revenue / Employee
$27,897
Employees
146
Market Cap
635.12M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.63M | 1.65M | 55.28% |
| Dec 31, 2024 | 2.98M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 462.25M |
| MiMedx Group | 355.17M |
| REGENXBIO | 174.48M |
| Valneva SE | 163.30M |
| Autolus Therapeutics | 117.39M |
| Verastem | 87.53M |
| OmniAb | 38.46M |
| Altimmune | 31.00K |
PRME News
- 7 days ago - Prime Medicine transferred with Buy rating at Chardan - TheFly
- 14 days ago - BMO starts Prime Medicine at Outperform into 2027 readouts - TheFly
- 14 days ago - Prime Medicine initiated with an Outperform at BMO Capital - TheFly
- 26 days ago - Prime Medicine reports Q4 EPS (24c), consensus (26c) - TheFly
- 26 days ago - Prime Medicine Quarterly report: Q2 2026 - Filings
- 26 days ago - Prime Medicine Earnings release: Q2 2026 - Filings
- 27 days ago - Prime Medicine Slides: Corporate presentation - Filings
- 5 weeks ago - Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - GlobeNewsWire